Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Castillo

Showing results (831-840 of 844) with videos related to

Pageof 85
Sort By:
Injury|October 23, 2024
Do the results of the OXYGEN trial change if analyzed as "as-treated?": A secondary analysis of the OXYGEN trialAugustine M Saiz, Anthony R Carlini, Renan C Castillo, et al.
Science (New York, N.Y.)|October 5, 2016
Cryovolcanism on CeresO Ruesch, T Platz, P Schenk, et al.
Nature|July 1, 2016
Bright carbonate deposits as evidence of aqueous alteration on (1) CeresM C De Sanctis, A Raponi, E Ammannito, et al.
BMJ Open|March 25, 2021
PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patientsRobert V O'Toole, Deborah M Stein, Katherine P Frey, et al.
Science (New York, N.Y.)|October 5, 2016
Distribution of phyllosilicates on the surface of CeresE Ammannito, M C DeSanctis, M Ciarniello, et al.
Biologicals : Journal of the International Association of Biological Standardization|October 31, 2009
Guidelines on stability evaluation of vaccinesR Dobbelaer, M Pfleiderer, M Haase, et al.
Science (New York, N.Y.)|October 5, 2016
Dawn arrives at Ceres: Exploration of a small, volatile-rich worldC T Russell, C A Raymond, E Ammannito, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 20, 2022
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in childrenRinaldo Puga-Gómez, Yariset Ricardo-Delgado, Chaumey Rojas-Iriarte, et al.
Human Mutation|October 13, 2005
Mutation rates at Y chromosome specific microsatellitesL Gusmão, P Sánchez-Diz, F Calafell, et al.
JAMA Surgery|December 20, 2018
Association Between 6-Week Postdischarge Risk Classification and 12-Month Outcomes After Orthopedic TraumaRenan C Castillo, Yanjie Huang, Daniel Scharfstein, et al.
Pageof 85

Showing results (831-840 of 844) with videos related to

Sort By:
Pageof 85
Injury|October 23, 2024
Do the results of the OXYGEN trial change if analyzed as "as-treated?": A secondary analysis of the OXYGEN trialAugustine M Saiz, Anthony R Carlini, Renan C Castillo, et al.
Science (New York, N.Y.)|October 5, 2016
Cryovolcanism on CeresO Ruesch, T Platz, P Schenk, et al.
Nature|July 1, 2016
Bright carbonate deposits as evidence of aqueous alteration on (1) CeresM C De Sanctis, A Raponi, E Ammannito, et al.
BMJ Open|March 25, 2021
PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patientsRobert V O'Toole, Deborah M Stein, Katherine P Frey, et al.
Science (New York, N.Y.)|October 5, 2016
Distribution of phyllosilicates on the surface of CeresE Ammannito, M C DeSanctis, M Ciarniello, et al.
Biologicals : Journal of the International Association of Biological Standardization|October 31, 2009
Guidelines on stability evaluation of vaccinesR Dobbelaer, M Pfleiderer, M Haase, et al.
Science (New York, N.Y.)|October 5, 2016
Dawn arrives at Ceres: Exploration of a small, volatile-rich worldC T Russell, C A Raymond, E Ammannito, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 20, 2022
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in childrenRinaldo Puga-Gómez, Yariset Ricardo-Delgado, Chaumey Rojas-Iriarte, et al.
Human Mutation|October 13, 2005
Mutation rates at Y chromosome specific microsatellitesL Gusmão, P Sánchez-Diz, F Calafell, et al.
JAMA Surgery|December 20, 2018
Association Between 6-Week Postdischarge Risk Classification and 12-Month Outcomes After Orthopedic TraumaRenan C Castillo, Yanjie Huang, Daniel Scharfstein, et al.
Pageof 85